Form 4: Hims & Hers Health CFO Oluyemi Okupe Executes Stock Option Exercises and Sales Under 10b5-1 Plan

Oluyemi Okupe, CFO of Hims & Hers Health, executed stock option exercises and sales of Class A Common Stock under a pre-arranged 10b5-1 trading plan.

Summary

• On May 20 and 21, 2024, Oluyemi Okupe, the Chief Financial Officer of Hims & Hers Health, Inc., engaged in transactions involving the company's Class A Common Stock.
• These transactions included the sale of 6,900 shares at an average price of $20.0063 on May 20, 2024.
• On May 21, 2024, Okupe exercised options to acquire 28,084 shares at a price of $5.01 per share.
• Following the option exercise, Okupe sold 31,433 shares at an average price of $17.8595, 3,349 shares at an average price of $17.9728, and another 3,349 shares at an average price of $17.9517, and a final 3,349 shares at an average price of $17.9517.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on May 10, 2023.
• After these transactions, Okupe directly owns 151,680 shares of Class A Common Stock and 936,311 derivative securities (stock options).

Sentiment

Score: 5

Explanation: Neutral sentiment as the transactions are part of a pre-planned trading strategy. The CFO selling shares could be seen as slightly negative, but the 10b5-1 plan mitigates concerns.

Positives

• The transactions were executed under a pre-arranged 10b5-1 trading plan, which is generally viewed as a transparent and compliant way for insiders to manage their stock holdings.

Negatives

• The CFO selling shares could be interpreted negatively by some investors, although it's part of a pre-planned strategy.

Risks

• While the 10b5-1 plan provides a framework, significant insider selling could still create short-term price volatility or negative sentiment.

Industry Context

Insider transactions are common and closely watched in the pharmaceutical and telehealth industries. Investors often analyze these filings for insights into management's confidence and the company's prospects.

Comparison to Industry Standards

• Comparing Okupe's transactions to those of CFOs at similar telehealth companies like Teladoc Health or Amwell could provide context.
• For example, if CFOs at comparable companies are also exercising options and selling shares under 10b5-1 plans, it might be viewed as a normal practice.
• However, if Okupe's selling activity is significantly higher than peers, it could raise concerns.

Stakeholder Impact

• Shareholders may react to the news of insider selling, potentially causing short-term price fluctuations.
• Employees holding stock options may be interested in the CFO's trading activity as it relates to the company's stock performance.

Key Dates